Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Person › Details

Greg Koytiger (Immuneering Corporation)

Koytiger, Greg (Immuneering 201811 SVP + Head of AI)

 

Organisation Organisation Immuneering Corporation
Products Product drug discovery software
  Product 2 artificial intelligence (AI) / machine learning (ML)
     

Evotec AG. (11/21/18). "Press Release: Evotec and Immuneering to Collaborate on Artifical Intelligence (“AI”) Driven Ligand Identification for Rare Hereditary Metabolic Diseases". Hamburg & Cambridge, MA.

COMBINATION OF CUTTING-EDGE IPSC AND AI TECHNOLOGIES CREATES OPPORTUNITY TO DISCOVER NOVEL METABOLIC LIGANDS TO ACCELERATE DRUG DISCOVERY IN RARE METABOLIC DISEASES


Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a research collaboration with Immuneering Corporation ("Immuneering"), a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases.

The research collaboration brings together Evotec's leading induced pluripotent stem cell ("iPSC") platform and broad drug discovery capabilities with Immuneering's unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets. As part of the collaboration, Evotec will use Immuneering's proprietary computational drug discovery platform Fluency to analyse public and proprietary data to advance identification of novel drug candidates that can ultimately lead to new medicines for rare hereditary metabolic diseases.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "We are very excited to collaborate with Immuneering on its unique AI-driven approach to ligand identification. This is a significant opportunity to develop novel drugs targeting disorders of lysosomes that drive different clinical presentations in many rare genetic metabolic and neurodegenerative diseases with high unmet medical need. We look forward to exploring the powerful combination of these technologies and enhancing our drug discovery capabilities in our core areas of focus."

Dr Greg Koytiger, SVP and Head of AI for Immuneering, said: "We are thrilled to combine Evotec's industry-leading iPSC platform with our AI platform, Fluency, to rapidly identify and functionally profile novel small molecule drugs for rare hereditary metabolic diseases. This not only accelerates the drug discovery process, but opens up new targets that are understudied or difficult to drug. Evotec's in-depth knowledge of targets of interest and their leading iPSC platform make them an ideal partner to transform in silico hits into breakthrough therapies. We look forward to integrating best in class experimental and computational approaches to break new ground together for the benefit of these patients."

No financial details of the alliance were disclosed.


ABOUT IMMUNEERING CORPORATION

Since its launch in February 2008, Immuneering has partnered with leading pharmaceutical companies to accelerate and improve the discovery and clinical development of novel drugs. The Immuneering team applies proprietary computational biology methods and an advanced drug discovery platform to high-throughput molecular data, re-engineering the process by which new medicines are discovered and developed to be faster, less expensive, and more likely to succeed. The company's proprietary drug discovery platform identifies "hits" (the molecular structures that form the basis of new medicines) in a matter of days or weeks, rather than the months or years of target identification and high-throughput screening typically required. This acceleration is made possible by applying artificial intelligence (AI) and other advanced algorithms to high-throughput data, and draws on Immuneering's decade of experience in applying high-throughput data to pharmaceutical R&D. Immuneering's team of experts also provides world-class bioinformatics and computational biology services. For additional information please go to www.immuneering.com and follow us on Twitter @Immuneering.


ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.


FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.


Contact Evotec AG:

Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

   
Record changed: 2018-11-21

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px


More documents for Greg Koytiger


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top